Medicines Co. picks up three EU approvals; Biogen, Samsung press on Remicade biosim;

@FierceBiotech: Skincare startup bags $50M to get its acne drug into Phase III. Story | Follow @FierceBiotech

@JohnCFierce: Big part of the $NVS/Aduro deal is that Dana Farber's Glenn Dranoff was tapped to run a new IO R&D group. More | Follow @JohnCFierce

@DamianFierce: Success for Sovaldi, a win for Vimizim and a eulogyto for Blincyto. #FierceMadness continues. More | Follow @DamianFierce

> The Medicines Company ($MDCO) picked up a trio of European approvals, winning nods for cangrelor, an anticoagulant rejected by the FDA last year; oritavancin, an antibiotic approved in the U.S. last year as Orbactiv; and Raplixa, a surgical sealant under FDA review. More

> The European Medicines Agency has accepted Biogen ($BIIB) and Samsung's application for a biosimilar of Johnson & Johnson's ($JNJ) blockbuster autoimmune treatment Remicade, setting the stage for an approval this year. News

> Israeli biotech Can-Fite's psoriasis drug failed to meet its primary endpoint in a Phase II/III study, sending the company's shares down by more than 50% on the Tel Aviv exchange. Item

Medical Device News

@FierceMedDev: Zimmer to divest three businesses to satisfy EU regulators in Biomet acquisition. Report | Follow @FierceMedDev

@VarunSaxena2: Outgoing FDA commissioner: Regulation, when done right, not a roadblock | National Press Club. More | Follow @VarunSaxena2

@EmilyWFierce: Horizon scoops up Hyperion and its rare disease portfolio for $1.1B. FiercePharma news | Follow @EmilyWFierce

> FDA taking 'very light touch' in smartphone and digital device regulation. Story

> Nanorobot shows promise as humidity sensor thanks to use of bacterial spore. Article

> Devicemaker, CEO, take on FDA over 'free speech' of sales pitch. More

Pharma News

@FiercePharma: Report: Pet owners clueless about obesity in their cats and dogs. FierceAnimalHealth item | Follow @FiercePharma

@EricPFierce: ICYMI: Genentech expansion adds to Roche biologics buildout. It promises 100 jobs, $125M outlay. Report | Follow @EricPFierce

@CarlyHFierce: $GSK finally seals U.K. Bexsero deal for £20 per dose. FierceVaccines story | Follow @CarlyHFierce

> Lilly execs take $3M hit to 2014 bonuses, but the pay freeze thaws for 2015. Report

> Horizon scoops up Hyperion and its rare disease portfolio for $1.1B. Article

Animal Health News

> Jaguar Animal Health eyes a second run at IPO. Report

> Critics say White House plan to combat antibiotic resistance falls 'woefully short.' More

> Report: Pet owners clueless about obesity in their cats and dogs. Item

> Gene testing and animal safety services drive double-digit growth at Neogen. Article

> U.K. scientists discover parasite protects cows against deadly East Coast fever. Story

Biotech IT News

> George Church backs online platform for open sharing of personal data. Report

> Committee clips the wings of Europe's controversial $1B brain project. Article

> Emerging markets tipped to push drug safety software market past $150M. Story

> NIH backs database of rare pediatric genetic disorders. Item

> 100,000 Genomes Project taps Big Pharma dream team for data crunching skills. More

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.